KCS
MCID: KRT001
MIFTS: 60

Keratoconjunctivitis Sicca (KCS)

Categories: Eye diseases, Rare diseases

Aliases & Classifications for Keratoconjunctivitis Sicca

MalaCards integrated aliases for Keratoconjunctivitis Sicca:

Name: Keratoconjunctivitis Sicca 12 76 53 29 55 44 15 73
Keratitis Sicca 53 73
Xerophthalmia 53 73
Dry Eye Syndromes 73
Dry Eye Syndrome 53
Kcs 12

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Eye diseases


External Ids:

Disease Ontology 12 DOID:12895
MeSH 44 D007638
SNOMED-CT 68 78946008

Summaries for Keratoconjunctivitis Sicca

MalaCards based summary : Keratoconjunctivitis Sicca, also known as keratitis sicca, is related to dry eye syndrome and keratoconjunctivitis, and has symptoms including eye manifestations, dryness of eye and dacryops. An important gene associated with Keratoconjunctivitis Sicca is LTF (Lactotransferrin), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Miconazole and Tocopherol have been mentioned in the context of this disorder. Affiliated tissues include eye, testes and liver, and related phenotypes are homeostasis/metabolism and immune system

Wikipedia : 76 Dry eye syndrome (DES), also known as keratoconjunctivitis sicca (KCS), is the condition of having dry... more...

Related Diseases for Keratoconjunctivitis Sicca

Diseases related to Keratoconjunctivitis Sicca via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 387)
# Related Disease Score Top Affiliating Genes
1 dry eye syndrome 32.1 IL6 LTF NGF TLR9 TNF
2 keratoconjunctivitis 32.0 IL4 NGF TLR9 TNF
3 corneal disease 30.5 IL1A NGF TLR9
4 lichen planus 30.4 IL4 TLR9 TNF
5 uveitis 30.2 IL10 IL1A IL4 TNF
6 chronic graft versus host disease 30.1 ALB CD79A IL10 IL1A TNF
7 oral cavity cancer 30.0 ERBB2 IL4 TLR9
8 arthritis 29.9 IL10 IL1A IL1B IL6 TNF
9 sleep apnea 29.8 IL1B IL6 TNF
10 juvenile rheumatoid arthritis 29.7 IL1B IL6 TNF
11 irritant dermatitis 29.7 IL1A IL1B TNF
12 rheumatoid arthritis 29.7 IL10 IL1A IL1B IL4 IL6 TNF
13 aspergillosis 29.7 IL10 IL4 TLR9 TNF
14 graft-versus-host disease 29.7 IL10 IL1A IL1B IL6 TNF
15 hematopoietic stem cell transplantation 29.6 IL10 IL6 TNF
16 dengue shock syndrome 29.6 IL1B IL6 TNF
17 diabetes mellitus 29.4 ALB IL1A IL1B IL6 TNF
18 colitis 29.3 IL10 IL1B IL4 IL6 TLR9 TNF
19 peritonitis 29.3 ALB IL10 IL1B IL6 TNF
20 chlamydia 29.3 CD79A IL10 IL1A IL1B IL4 IL6
21 osteoporosis 29.2 ALB IL1A IL1B IL6 TNF
22 appendicitis 29.1 ALB IL10 IL1B IL6 TNF
23 chronic fatigue syndrome 29.1 IL10 IL1B IL6 TNF
24 otitis media 29.0 ALB CD79A IL10 IL1B IL4 IL6
25 autoimmune disease 29.0 CD79A IL10 IL1B IL4 IL6 TLR9
26 systemic lupus erythematosus 28.5 ALB CD79A IL10 IL1B IL4 IL6
27 xerophthalmia 12.7
28 sjogren syndrome 12.3
29 myelopathy, htlv-1-associated 11.3
30 aplasia of lacrimal and salivary glands 11.3
31 tropical spastic paraparesis 11.3
32 retrovirus-associated myelopathy 11.3
33 kenny-caffey syndrome, type 1 11.2
34 kenny-caffey syndrome, type 2 11.0
35 keratoconus posticus circumscriptus 11.0
36 premature ovarian failure 1 11.0
37 keratomalacia 10.7
38 hypercarotenemia and vitamin a deficiency, autosomal dominant 10.6
39 japanese encephalitis 10.5
40 skin conditions 10.3 IL1A TNF
41 autoimmune myocarditis 10.3 IL4 TNF
42 night blindness 10.2
43 hyperlucent lung 10.2 IL10 IL4
44 pouchitis 10.2 IL10 LTF
45 ocular cicatricial pemphigoid 10.2 CD79A IL4 NGF
46 sporotrichosis 10.2 CD79A IL10
47 b-cell growth factor 10.2 IL4 IL6
48 root caries 10.2 ALB CD79A LTF
49 congenital hypogammaglobulinemia 10.2 CD79A IL1A IL4
50 endocrine gland cancer 10.2 ALB ERBB2 TLR9

Graphical network of the top 20 diseases related to Keratoconjunctivitis Sicca:



Diseases related to Keratoconjunctivitis Sicca

Symptoms & Phenotypes for Keratoconjunctivitis Sicca

UMLS symptoms related to Keratoconjunctivitis Sicca:


eye manifestations, dryness of eye, dacryops

MGI Mouse Phenotypes related to Keratoconjunctivitis Sicca:

46 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.35 ALB CD79A ERBB2 ERBB3 HSPG2 IL10
2 immune system MP:0005387 10.3 CD79A CLEC4F ERBB3 HSPG2 IL10 IL1A
3 cellular MP:0005384 10.28 ALB CD79A ERBB2 ERBB3 HSPG2 IL10
4 hematopoietic system MP:0005397 10.27 CD79A CLEC4F HSPG2 IL10 IL1A IL1B
5 cardiovascular system MP:0005385 10.25 ERBB2 ERBB3 HSPG2 IL10 IL1A IL1B
6 digestive/alimentary MP:0005381 10.22 ALB ERBB2 ERBB3 HSPG2 IL10 IL4
7 mortality/aging MP:0010768 10.15 ALB ERBB2 ERBB3 HSPG2 IL10 IL1B
8 integument MP:0010771 10.13 ERBB2 ERBB3 HSPG2 IL10 IL1A IL1B
9 endocrine/exocrine gland MP:0005379 10.11 ALB ERBB2 ERBB3 IL10 IL4 IL6
10 liver/biliary system MP:0005370 10.01 ALB CD79A HSPG2 IL10 IL4 IL6
11 muscle MP:0005369 9.97 ALB ERBB2 ERBB3 HSPG2 IL10 IL6
12 neoplasm MP:0002006 9.96 ALB CD79A ERBB2 ERBB3 IL10 IL1A
13 nervous system MP:0003631 9.9 CD79A ERBB2 ERBB3 HSPG2 IL10 IL1B
14 normal MP:0002873 9.56 ALB CD79A ERBB2 ERBB3 IL10 IL4
15 respiratory system MP:0005388 9.17 ERBB2 ERBB3 HSPG2 IL10 IL4 IL6

Drugs & Therapeutics for Keratoconjunctivitis Sicca

Drugs for Keratoconjunctivitis Sicca (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 376)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
2
Tocopherol Approved, Investigational Phase 4,Not Applicable 1406-66-2 14986
3
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 9004-61-9 53477741
4
Povidone Approved Phase 4,Not Applicable 9003-39-8
5
Ephedrine Approved Phase 4 299-42-3 9294
6
Pseudoephedrine Approved Phase 4 90-82-4 7028
7
Dipivefrin Approved Phase 4,Phase 3,Phase 1,Not Applicable 52365-63-6 3105
8
Travoprost Approved Phase 4 157283-68-6 5282226
9
Prednisone Approved, Vet_approved Phase 4,Phase 1 53-03-2 5865
10
Calcium Carbonate Approved, Investigational Phase 4 471-34-1
11
Cyclophosphamide Approved, Investigational Phase 4 6055-19-2, 50-18-0 2907
12
Loteprednol Approved, Experimental Phase 4,Phase 3,Phase 2,Not Applicable 82034-46-6, 129260-79-3 9865442 444025
13
Glycerol Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 56-81-5 753
14
Tobramycin Approved, Investigational Phase 4,Phase 1,Not Applicable 32986-56-4 36294 5496
15
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-02-2 5743
16
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1177-87-3
17 Lifitegrast Approved Phase 4,Phase 3,Phase 2,Not Applicable 1025967-78-5
18
Isotretinoin Approved Phase 4 4759-48-2 5538 5282379
19
Ethanol Approved Phase 4,Phase 2,Not Applicable 64-17-5 702
20
Zinc Approved, Investigational Phase 4,Phase 2,Not Applicable 7440-66-6
21
Menthol Approved Phase 4 2216-51-5 16666
22
Tacrolimus Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 104987-11-3 445643 439492
23
Azithromycin Approved Phase 4 83905-01-5 55185 447043
24
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 1 50-24-8 5755
25
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 1 83-43-2 6741
26
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
27
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 1 302-25-0
28
Ofloxacin Approved Phase 4 82419-36-1 4583
29
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 1 2921-57-5
30
Ketorolac Approved Phase 4,Phase 2 66635-83-4, 74103-06-3 3826
31
Dorzolamide Approved Phase 4 120279-96-1 5284549 3154
32
Timolol Approved Phase 4,Phase 3 26839-75-8 33624 5478
33
Latanoprost Approved, Investigational Phase 4,Phase 3,Not Applicable 130209-82-4 5311221 5282380
34
Dimenhydrinate Approved Phase 4,Not Applicable 523-87-5 441281
35
Pilocarpine Approved, Investigational Phase 4 54-71-7, 92-13-7 5910
36
Sulfacetamide Approved Phase 4 144-80-9 5320
37
Mineral oil Approved, Vet_approved Phase 4 8042-47-5
38
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
39
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 2,Not Applicable 564-25-0 54671203
40
Minocycline Approved, Investigational Phase 4 10118-90-8 5281021
41
Doxazosin Approved Phase 4 74191-85-8 3157
42
Ganciclovir Approved, Investigational Phase 4 82410-32-0 3454
43
Oxybutynin Approved, Investigational Phase 4,Not Applicable 5633-20-5 4634
44 sodium fluoride Approved Phase 4,Not Applicable 7681-49-4
45
Allantoin Approved Phase 4,Not Applicable 97-59-6 204
46 tannic acid Approved Phase 4,Not Applicable
47
Benzocaine Approved, Investigational Phase 4,Not Applicable 94-09-7, 1994-09-7 2337
48
Sorbitol Approved Phase 4,Not Applicable 50-70-4 5780
49
Acetylcholine Approved Phase 4,Phase 1 51-84-3 187
50
Lymecycline Approved, Investigational Phase 4 992-21-2 5280963

Interventional clinical trials:

(show top 50) (show all 868)
# Name Status NCT ID Phase Drugs
1 Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus Unknown status NCT00797030 Phase 4 cyclosporine and sodium carboximethycellulose;sodium carboximethycellulose
2 Oral Nutrition Impact on Tear Film Unknown status NCT01561040 Phase 4
3 Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes Unknown status NCT00704275 Phase 4 0.05% cyclosporin eye drop
4 Altaire Gel Forming Solution Versus Refresh Tears for the Treatment of Dry Eye Signs and Symptoms Unknown status NCT01382810 Phase 4 Altaire Gel forming solution;Refresh Tears
5 0.3% Sodium Hyaluronate in the Treatment of Dry Eye of Diabetic Patients Unknown status NCT02595606 Phase 4 0.3% Sodium Hyaluronate
6 Efficacy of FreshKote and Systane for the Treatment of Dry Eye and Improvement of Osmolarity Unknown status NCT01386073 Phase 4 FreshKote;Systane
7 Effect of Intense Pulse Light (IPL) Treatment on Tear Film Osmolarity Unknown status NCT02992535 Phase 4
8 Tear Osmolarity Over Time With Artificial Tears Unknown status NCT01227226 Phase 4 Artificial tears
9 Hyaluronic Acid Gels for Upper Lid Retraction in Active Stage Thyroid Eye Disease Unknown status NCT01738243 Phase 4 Hyaluronic Acid Gel injection;Saline injection
10 Generic Travoprost Versus Brand Name Travoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension Unknown status NCT02796560 Phase 4 Brand name travoprost;Generic travoprost
11 Cyclosporine A in the TReatment of Interstitial Pneumonitis Associated With Sjogren's Syndrome Unknown status NCT02370550 Phase 4 Cyclosporin A;Prednisone;Placebo;Calcium carbonate D
12 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
13 Sex Steroids in Sjögren's Syndrome: Effect of Substitution Treatment on Fatigue Unknown status NCT00543166 Phase 4 dehydroepiandrosterone
14 Effect of Lifitegrast on Dry Eye Disease Signs and Symptoms Completed NCT03451396 Phase 4 Lifitegrast
15 The Comparison of 50% AS Versus PFAT+ 0.05 % COE in Severe Dry Eye Syndrome Completed NCT03666884 Phase 4 COE 2*1 (Restasis) + PFAT Refresh Single dose) 8*1
16 Efficacy of Cyclosporine for the Prevention and Treatment of Dry Eye Symptoms Following LASIK or Photorefractive Keratectomy Completed NCT00349440 Phase 4 Cyclosporine, Refresh Plus
17 A Phase 4 Study Investigating the Efficacy of Retaine™ in Managing Signs and Symptoms Associated With Dry Eye Syndrome Completed NCT02139033 Phase 4 Retaine™
18 Comparison of Autologous Serum Versus Preservative Free Artificial Tear Completed NCT02752763 Phase 4 %40 diluted Autologous serum;Preservative free artificial tears(Tears naturale free, Refresh single dose eye drop)
19 Influence of Lachrymal Substitutes on Tear Film Thickness in Patients With Moderate Dry Eye Syndrome Completed NCT01864330 Phase 4
20 Comparative Study of Rohto Dry-Aid® and Systane® Ultra in Patients With Dry Eye Completed NCT03183089 Phase 4 Rohto Dry-Aid®;Systane® Ultra
21 Kynex Versus Refresh Plus Study in Subject With Dry Eye Completed NCT00809198 Phase 4
22 Comparative Study of 0.5% Carboxymethylcellulose With 0.005% Stabilized Oxychlorocomplex (PURITE™) Versus 0.5% Carboxymethylcellulose in the Treatment of Dry Eye Completed NCT00386646 Phase 4 0.5% carboxymethylcellulose (CMC) with purite and CMC alone
23 Efficacy and Safety of a Treatment for Dry Eye Syndrome: Thealoz Completed NCT01742884 Phase 4
24 A Study to Determine the Relief of Dry Eye Symptoms With the Use of TheraTears® Products (DUNLIN) Completed NCT02014922 Phase 4 TheraTears® Lubricant Eye Drop;TheraTears® preservative-free single-use containers
25 Efficacy of Optive Versus Systane Concomitant With Restasis (Cyclosporine A) for the Treatment of Dry Eye Symptoms Completed NCT00399061 Phase 4 Systane, Optive, Restasis
26 Objective Measurements of Prolonged Effects of Restasis on Dry Eye Disease Completed NCT00567177 Phase 4 Restasis, Refresh Plus
27 A Prospective, Randomized, Double-Masked, Single Center, Clinical Comparison of the Use of Systane Ultra in the Management of Dry Eyes in Bilateral Eyes Completed NCT00781092 Phase 4
28 Evaluate Artificial Tear Efficacy in Moderate to Severe Dry Eye Completed NCT00724412 Phase 4
29 A Study of the Effect of Zinc-Hyaluronate on Ocular Surface Sensations in Patients With Dry Eye Completed NCT02951910 Phase 4
30 Multicenter, Randomized, Controlled Study of the Effect of Lotemax on Initiation of Dry Eye Treatment With Restasis Completed NCT00407043 Phase 4 Lotemax;Restasis
31 Bilateral, Masked Comparison of PEG-400 Based Artificial Tear vs. Systane for Dry Eye Signs, Symptoms & Refractive Regression Associated With Myopic Laser in Situ Keratomilieusis (LASIK). Completed NCT00620893 Phase 4 PEG- 400 based artificial tear;Systane
32 Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye Completed NCT00987727 Phase 4 carboxymethylcellulose 0.5% , glycerin 0.9% (OPTIVE® MD);sodium hyaluronate 0.18% (VISMED® Multi)
33 Symptom Response in Normal and Dry Eye Patients Secondary to Application of a Menthol-Containing Eyedrop (Rohto® Hydra) Completed NCT02985827 Phase 4 Rohto (r) Hydra;Systane (r) Ultra
34 Influence of Lachrymal Substitute Gels on Tear Film Thickness in Patients With Moderate to Severe Dry Eye Syndrome Completed NCT02585453 Phase 4
35 Pilot Study on the Use of Artificial Tears to Treat Dry Eye in Glaucoma Patients Completed NCT01682460 Phase 4 Refresh Tears Lubricant Eye Drops (Allergan)
36 Safety and Efficacy of Optive in Contact Lens Wearers With Dry Eyes Completed NCT00469573 Phase 4 1. Optive
37 Comparison of Systane Free vs. Saline in the Treatment of Dry Eye Completed NCT00388791 Phase 4 Systane Free
38 A Clinical Evaluation Pilot Study of the Efficacy of Blink® Tears Lubricant Eye Drops for the Relief of Dry Eye Symptoms Following Implantation of Tecnis® Multifocal Introcular Lens Completed NCT01061268 Phase 4 No topical artificial tear;Blink® Tears Lubricant Eye Drops
39 The Effect of Ocular Lubricant Eyedrops on Lid Parallel Conjunctival Folds and Other Signs and Symptoms of Dry Eye Completed NCT01268735 Phase 4 Lubricating eyedrops containing hydroxypropyl-guar
40 Efficacy and Safety of a New Multi-dose Lubricant Eye Drop Concomitant With Restasis® (Cyclosporine A) for the Treatment of Dry Eye Symptoms Completed NCT00405457 Phase 4 Restasis, Optive Tears
41 Bilateral, Masked Comparison of PEG-400 Based Artificial Tear and Systane for the Treatment of Dry Eye Signs, Symptoms and Visual Quality Completed NCT00622037 Phase 4 PEG-400 based artificial tear;Systane
42 Treatment of Dry Eye Using 0.03% Tacrolimus Eye Drops Completed NCT01850979 Phase 4 Tacrolimus;Olive Oil
43 Safety and Efficacy of Punctal Plug Insertion in Patients With Dry Eye Completed NCT01684436 Phase 4
44 Efficacy of Systane Ultra in Post Menopausal Women With Dry Eye Completed NCT01105910 Phase 4
45 Safety Study of the Use of Topical Cyclosporine in the Treatment of Dry Eye Disease Completed NCT02004067 Phase 4 Restasis;Refresh Endura
46 Efficacy of 0.05% Cyclosporin Eye Drop in Stevens Johnson Syndrome Patient With Chronic Dry Eye Completed NCT01488396 Phase 4 0.05%cyclosporin eye drop
47 A Safety and Efficacy Study of OPTIVE FUSION™ With VISMED® Multi for the Management of Dry Eye Completed NCT02117687 Phase 4 carboxymethylcellulose 0.5%/glycerin 0.9%;sodium hyaluronate 0.18%
48 Efficacy Study of a New Eyedrop on Silicone Hydrogel Contact Lens Wearers With Dry Eye Complaints Completed NCT01543061 Phase 4
49 The Utility of IVCM to Assess Cellular Response and Efficacy of Long-term Topical Steroid Treatment in Patients With DED Completed NCT02120079 Phase 4 Lotemax;Soothe Tired Eyes Lubricant Eye Drop (Artificial Tears)
50 Study to Compare the Efficacy and Safety of Two Non-Preserved Artificial Tears for the Treatment of Dry Eye Signs and Symptoms Completed NCT00938704 Phase 4 carboxymethylcellulose 0.5% +glycerin 0.9%;sodium hyaluronate 0.18%

Search NIH Clinical Center for Keratoconjunctivitis Sicca

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: keratoconjunctivitis sicca

Genetic Tests for Keratoconjunctivitis Sicca

Genetic tests related to Keratoconjunctivitis Sicca:

# Genetic test Affiliating Genes
1 Keratoconjunctivitis Sicca 29

Anatomical Context for Keratoconjunctivitis Sicca

MalaCards organs/tissues related to Keratoconjunctivitis Sicca:

41
Eye, Testes, Liver, T Cells, Lung, Heart, B Cells

Publications for Keratoconjunctivitis Sicca

Articles related to Keratoconjunctivitis Sicca:

(show top 50) (show all 388)
# Title Authors Year
1
Assessment of corneal and conjunctival metaplasia by impression cytology during the treatment of canine keratoconjunctivitis sicca. ( 29958527 )
2018
2
Immunohistochemical evaluation of lymphocyte populations in the nictitans glands of normal dogs and dogs with keratoconjunctivitis sicca. ( 29445621 )
2018
3
Efficacy of HL036 versus Cyclosporine A in the Treatment of Naturally Occurring Canine Keratoconjunctivitis Sicca. ( 29634381 )
2018
4
Autonomic reinnervation and functional regeneration in autologous transplanted submandibular glands in patients with severe keratoconjunctivitis sicca. ( 29695713 )
2018
5
Suppression of Th1-Mediated Keratoconjunctivitis Sicca by Lifitegrast. ( 29958030 )
2018
6
Nuclear parameters and chromatin remodeling in epithelial cells and lymphocytes from the palpebral conjunctiva of dogs with keratoconjunctivitis sicca. ( 29493861 )
2018
7
Optimising tear replacement rheology in canine keratoconjunctivitis sicca. ( 29303147 )
2018
8
Clinical trials with multiple endpoints can establish a correlation, but not (yet) causality, between dietary supplementation with omega-3 fatty acids and keratoconjunctivitis sicca. ( 29781353 )
2018
9
Microvascular Submandibular Gland Transplantation for Severe Keratoconjunctivitis Sicca: A Single-Institution Experience of 56 Cases. ( 29864431 )
2018
10
Rheumatoid factor isotype and Ro epitope distribution in primary SjAPgren syndrome and rheumatoid arthritis with keratoconjunctivitis sicca. ( 29936570 )
2018
11
Use of clinical vignette questionnaires to investigate the variation in management of keratoconjunctivitis sicca and acute glaucoma in dogs. ( 29275324 )
2018
12
Efficacy of Trabodenoson in a Mouse Keratoconjunctivitis Sicca (KCS) Model for Dry-Eye Syndrome. ( 30025146 )
2018
13
Comparison of the efficacy of 0.03% tacrolimus eye drops diluted in olive oil and linseed oil for the treatment of keratoconjunctivitis sicca in dogs. ( 29995121 )
2018
14
Oral omega 3 in different proportions of EPA, DHA, and antioxidants as adjuvant in treatment of keratoconjunctivitis sicca in dogs. ( 30208145 )
2018
15
Severity of Sjögren's Syndrome Keratoconjunctivitis Sicca Increases with Increased Percentage of Conjunctival Antigen-Presenting Cells. ( 30223431 )
2018
16
Phenotypic features and predictors of the clinical severity of keratoconjunctivitis sicca and salivary gland dysfunction in patients with Sjögren's syndrome: a longitudinal analysis of the Korean Initiative of primary Sjögren's Syndrome (KISS) cohort. ( 30475093 )
2018
17
Canine oral mucosa evaluation as a potential autograft tissue for the treatment of unresponsive keratoconjunctivitis sicca. ( 28470741 )
2017
18
Polyparaneoplastic Manifestations of Malignant Thymoma: A Unique Case of Myasthenia, Autoimmune Hepatitis, Pure Red Cell Aplasia, and Keratoconjunctivitis Sicca. ( 28744421 )
2017
19
Comparison between fish and linseed oils administered orally for the treatment of experimentally induced keratoconjunctivitis sicca in rabbits. ( 29038781 )
2017
20
Tear ferning in normal dogs and dogs with keratoconjunctivitis sicca. ( 29038779 )
2017
21
Scleral lenses for severe chronic GvHD-related keratoconjunctivitis sicca: a retrospective study by the SFGM-TC. ( 28218751 )
2017
22
Immediate Effect of 3% Diquafosol Ophthalmic Solution on Tear MUC5AC Concentration and Corneal Wetting Ability in Normal and Experimental Keratoconjunctivitis Sicca Rat Models. ( 27791390 )
2017
23
A novel treatment for keratitis sicca (Dry eye): Anatomical feasibility study. ( 28631333 )
2017
24
Carbachol improves the secretion of transplanted submandibular glands during the latent period after microvascular autologous transplantation for severe keratoconjunctivitis sicca. ( 27094607 )
2016
25
Allogeneic Mesenchymal Stem Cell Transplantation in Dogs With Keratoconjunctivitis Sicca. ( 28003932 )
2016
26
Episcleral cyclosporine A implants for the management of unilateral keratoconjunctivitis sicca in an 8-year-old mare. ( 26945681 )
2016
27
Assessment of tear film osmolarity using the TearLab(a8c) osmometer in normal dogs and dogs with keratoconjunctivitis sicca. ( 27761982 )
2016
28
Comparative clinical evaluation of tacrolimus and cyclosporine eye drops for the treatment of canine keratoconjunctivitis sicca. ( 27653428 )
2016
29
Clinical evaluation of a nutraceutical diet as an adjuvant to pharmacological treatment in dogs affected by Keratoconjunctivitis sicca. ( 27658509 )
2016
30
Increased Straylight in Patients With Keratoconjunctivitis Sicca. ( 27490054 )
2016
31
Increased Straylight in Patients With Keratoconjunctivitis Sicca. ( 27032024 )
2016
32
Outcomes of different concentrations of human amniotic fluid in a keratoconjunctivitis sicca-induced mouse model. ( 26767655 )
2016
33
Pimecrolimus micelle exhibits excellent therapeutic effect for Keratoconjunctivitis Sicca. ( 26731192 )
2016
34
Keratoconjunctivitis sicca exacerbation in a dog treated with systemic atenolol. ( 27071733 )
2016
35
Erratum to: Clinical evaluation of a nutraceutical diet as an adjuvant to pharmacological treatment in dogs affected by Keratoconjunctivitis sicca. ( 27919262 )
2016
36
Clinical and light microscopic studies of the conjunctival tissues of dogs with bilateral keratoconjunctivitis sicca before and after treatment with topical 2% cyclosporine. ( 25747049 )
2015
37
Human albumin eye drops as a therapeutic option for the management of keratoconjunctivitis sicca secondary to chronic graft-versus-host disease after stem-cell allografting. ( 26628876 )
2015
38
Effect of once daily topical 0.3% naltrexone on tear parameters and corneal sensitivity in dogs with uncontrolled keratoconjunctivitis sicca: a double-masked randomized placebo-controlled clinical trial. ( 25675975 )
2015
39
Salivary gland scintigraphy in patients suffering from severe keratoconjunctivitis sicca. Evaluation of the viability of submandibular glands before and after transfer into the temporal fossa. ( 26083667 )
2015
40
Microvascular autologous submandibular gland transplantation in severe cases of keratoconjunctivitis sicca. ( 25664315 )
2015
41
Comparison of 1% cyclosporine eye drops in olive oil and in linseed oil to treat experimentally-induced keratoconjunctivitis sicca in rabbits. ( 26466228 )
2015
42
Use of adipose-derived mesenchymal stem cells in keratoconjunctivitis sicca in a canine model. ( 25802852 )
2015
43
Immune-mediated keratoconjunctivitis sicca in dogs: current perspectives on management. ( 30101119 )
2015
44
Autoimmunity in the pathogenesis and treatment of keratoconjunctivitis sicca. ( 24395332 )
2014
45
Recurrent microbial keratitis in eyes with keratoconjunctivitis sicca with coexisting ocular surface pathology. ( 25378890 )
2014
46
Retrospective study of the prevalence of keratoconjunctivitis sicca in diabetic and nondiabetic dogs after phacoemulsification. ( 25429857 )
2014
47
Effect of rebamipide ophthalmic suspension on signs and symptoms of keratoconjunctivitis sicca in SjAPgren syndrome patients with or without punctal occlusions. ( 24977983 )
2014
48
The Role of Chlamydia Pneumoniae in the Etiology Keratoconjunctivitis Sicca (KCS). ( 25395268 )
2014
49
Use of episcleral cyclosporine implants in dogs with keratoconjunctivitis sicca: pilot study. ( 24799029 )
2014
50
Uveodermatologic syndrome concurrent with keratoconjunctivitis sicca in a miniature poodle dog. ( 24891645 )
2014

Variations for Keratoconjunctivitis Sicca

Expression for Keratoconjunctivitis Sicca

Search GEO for disease gene expression data for Keratoconjunctivitis Sicca.

Pathways for Keratoconjunctivitis Sicca

Pathways related to Keratoconjunctivitis Sicca according to GeneCards Suite gene sharing:

(show top 50) (show all 67)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.06 CD79A ERBB2 ERBB3 IL10 IL1A IL1B
2
Show member pathways
13.88 ERBB2 ERBB3 HSPG2 IL10 IL1A IL1B
3
Show member pathways
13.71 ERBB2 ERBB3 IL10 IL1A IL1B IL4
4
Show member pathways
13.59 ERBB2 ERBB3 IL10 IL1A IL1B IL4
5
Show member pathways
13.39 ERBB2 ERBB3 IL10 IL1A IL1B IL4
6
Show member pathways
13.39 ERBB2 ERBB3 IL10 IL1A IL1B IL4
7
Show member pathways
13.34 ERBB2 IL10 IL1A IL1B IL4 IL6
8
Show member pathways
13.25 CD79A ERBB2 ERBB3 IL1A IL1B IL4
9
Show member pathways
13.03 ERBB2 ERBB3 IL4 IL6 NGF TNF
10
Show member pathways
12.92 IL10 IL1A IL1B IL4 IL6 TNF
11
Show member pathways
12.86 IL1A IL1B IL4 IL6 TLR9 TNF
12 12.83 ERBB2 ERBB3 IL1A IL1B NGF TNF
13
Show member pathways
12.76 IL1A IL1B IL6 NGF TLR9 TNF
14
Show member pathways
12.65 IL1A IL1B NGF TLR9 TNF
15
Show member pathways
12.65 IL10 IL1A IL1B IL4 IL6 TNF
16
Show member pathways
12.64 ERBB2 IL10 IL1B IL6 TNF
17 12.62 CD79A IL10 IL1B IL4 TLR9 TNF
18
Show member pathways
12.46 IL10 IL1A IL1B IL4 IL6 TNF
19
Show member pathways
12.45 ERBB2 ERBB3 IL1A IL1B
20
Show member pathways
12.4 ALB IL1B IL4 IL6 TNF
21
Show member pathways
12.39 HSPG2 IL1A IL1B IL6 TNF
22
Show member pathways
12.36 IL1B IL4 IL6 TNF
23 12.33 ERBB2 ERBB3 HSPG2 TNF
24
Show member pathways
12.33 IL10 IL1A IL1B IL4 TNF
25
Show member pathways
12.3 IL1A IL6 TLR9 TNF
26
Show member pathways
12.28 IL10 IL1B IL6 TLR9 TNF
27
Show member pathways
12.27 IL1A IL1B IL6 TNF
28
Show member pathways
12.25 IL1B IL4 IL6 TLR9 TNF
29
Show member pathways
12.25 IL10 IL1A IL1B IL4 IL6 NGF
30 12.24 IL10 IL1A IL1B IL6 TLR9 TNF
31
Show member pathways
12.14 IL10 IL1A IL1B IL4 IL6 NGF
32
Show member pathways
12.12 IL10 IL1B IL6 TLR9 TNF
33 12.12 IL10 IL1A IL1B IL6 NGF TNF
34
Show member pathways
12.1 HSPG2 IL1B IL4 IL6 TNF
35
Show member pathways
12.09 ERBB2 ERBB3 IL1A IL1B TLR9
36 12.07 IL1A IL1B IL4 IL6 TNF
37 12.05 CD79A IL10 IL4 IL6 TNF
38 11.99 IL1A IL1B IL6 TNF
39 11.97 IL10 IL1B IL6 TNF
40 11.96 IL1B IL6 TNF
41 11.94 IL1A IL1B IL6
42 11.94 IL1A IL1B IL4 IL6 TNF
43 11.93 IL1A IL1B IL6 TNF
44 11.9 IL10 IL1A IL1B IL4 IL6 TNF
45 11.87 IL10 IL1B IL4 TNF
46 11.84 IL1A IL1B IL6
47 11.8 IL10 IL1A IL1B IL6 TNF
48 11.75 IL1B IL4 IL6 TNF
49
Show member pathways
11.75 IL1A IL1B IL6 TNF
50 11.74 IL10 IL1B IL6 TLR9 TNF

GO Terms for Keratoconjunctivitis Sicca

Cellular components related to Keratoconjunctivitis Sicca according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.7 ALB ERBB3 HSPG2 IL10 IL1A IL1B
2 extracellular region GO:0005576 9.44 ALB ERBB3 HSPG2 IL10 IL1A IL1B

Biological processes related to Keratoconjunctivitis Sicca according to GeneCards Suite gene sharing:

(show top 50) (show all 62)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.97 IL1B LTF TLR9 TNF
2 cellular response to lipopolysaccharide GO:0071222 9.96 IL10 IL1B IL6 TNF
3 MAPK cascade GO:0000165 9.92 ERBB2 ERBB3 IL1B NRTN TNF
4 positive regulation of MAPK cascade GO:0043410 9.91 ERBB2 ERBB3 IL6 TLR9
5 immune response GO:0006955 9.91 IL10 IL1A IL1B IL4 IL6 TLR9
6 wound healing GO:0042060 9.9 ERBB2 ERBB3 IL1B
7 defense response to Gram-negative bacterium GO:0050829 9.9 IL6 LTF TLR9
8 positive regulation of JNK cascade GO:0046330 9.89 IL1B TLR9 TNF
9 B cell differentiation GO:0030183 9.88 CD79A IL10 IL4
10 cytokine-mediated signaling pathway GO:0019221 9.88 IL10 IL1A IL1B IL4 IL6 TNF
11 positive regulation of DNA-binding transcription factor activity GO:0051091 9.87 IL10 IL1B IL6 TNF
12 positive regulation of T cell proliferation GO:0042102 9.86 IL1B IL4 IL6
13 humoral immune response GO:0006959 9.86 IL6 LTF TNF
14 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.85 IL1B TLR9 TNF
15 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.85 ERBB2 ERBB3 NGF NRTN
16 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.83 IL1B IL6 LTF TLR9 TNF
17 positive regulation of JUN kinase activity GO:0043507 9.81 IL1B TLR9 TNF
18 inflammatory response GO:0006954 9.8 HSPG2 IL10 IL1A IL1B IL6 TLR9
19 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.79 IL1A IL1B TNF
20 extrinsic apoptotic signaling pathway in absence of ligand GO:0097192 9.78 ERBB3 IL1A IL1B
21 response to glucocorticoid GO:0051384 9.78 IL10 IL1B IL6 TNF
22 negative regulation of interleukin-6 production GO:0032715 9.77 IL10 TLR9 TNF
23 peripheral nervous system development GO:0007422 9.77 ERBB2 ERBB3 NGF
24 positive regulation of cytokine secretion GO:0050715 9.76 IL10 IL1A TNF
25 positive regulation of interleukin-6 production GO:0032755 9.76 IL1B IL6 TLR9 TNF
26 negative regulation of apoptotic process GO:0043066 9.76 ALB ERBB2 ERBB3 IL10 IL4 IL6
27 positive regulation of interleukin-8 production GO:0032757 9.75 IL1B TLR9 TNF
28 negative regulation of growth of symbiont in host GO:0044130 9.73 IL10 TNF
29 nerve development GO:0021675 9.73 NGF NRTN
30 negative regulation of neurogenesis GO:0050768 9.73 IL1B IL6 TNF
31 positive regulation of interleukin-2 biosynthetic process GO:0045086 9.72 IL1A IL1B
32 response to molecule of bacterial origin GO:0002237 9.72 IL10 TLR9
33 positive regulation of granulocyte macrophage colony-stimulating factor production GO:0032725 9.72 IL1B TLR9
34 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.71 TLR9 TNF
35 negative regulation of lipid storage GO:0010888 9.71 IL6 TNF
36 positive regulation of chemokine production GO:0032722 9.71 IL6 TLR9 TNF
37 endothelial cell apoptotic process GO:0072577 9.7 IL10 TNF
38 positive regulation of chemokine biosynthetic process GO:0045080 9.7 IL1B TNF
39 ectopic germ cell programmed cell death GO:0035234 9.7 IL1A IL1B
40 negative regulation of interleukin-8 production GO:0032717 9.69 IL10 TLR9
41 positive regulation of MHC class II biosynthetic process GO:0045348 9.69 IL10 IL4
42 regulation of establishment of endothelial barrier GO:1903140 9.69 IL1B TNF
43 positive regulation of glial cell proliferation GO:0060252 9.69 IL1B IL6 TNF
44 negative regulation of cytokine secretion involved in immune response GO:0002740 9.68 IL10 TNF
45 positive regulation of fever generation GO:0031622 9.67 IL1B TNF
46 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.67 IL10 IL1B TNF
47 chronic inflammatory response to antigenic stimulus GO:0002439 9.65 IL1B TNF
48 regulation of isotype switching GO:0045191 9.65 IL10 IL4
49 sequestering of triglyceride GO:0030730 9.65 IL1B TNF
50 type 2 immune response GO:0042092 9.64 IL10 IL4

Molecular functions related to Keratoconjunctivitis Sicca according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transmembrane signaling receptor activity GO:0004888 9.56 CD79A ERBB2 ERBB3 TLR9
2 growth factor activity GO:0008083 9.35 IL10 IL4 IL6 NGF NRTN
3 interleukin-1 receptor binding GO:0005149 9.33 IL1A IL1B TLR9
4 cytokine activity GO:0005125 9.1 IL10 IL1A IL1B IL4 IL6 TNF

Sources for Keratoconjunctivitis Sicca

3 CDC
7 CNVD
9 Cosmic
10